The markedly increased AR expression that is already occurring at early times of BRAFi and MEKi exposure suggested that this molecule can fulfill a second distinct function in melanoma cells as part of an adaptive mechanism leading to targeted drug resistance. The gene discussed is AR; the disease is melanoma.